Clinical Report: Ofatumumab-Induced Remission in Refractory Panuveitis
Overview
This case report discusses a patient with refractory non-infectious panuveitis and multiple sclerosis who achieved sustained clinical remission after treatment with ofatumumab, a B-cell–depleting monoclonal antibody. The findings suggest a potential role for B-cell-targeted therapies in managing refractory uveitis, particularly in patients with coexisting autoimmune conditions.
Background
Non-infectious uveitis is a significant cause of visual impairment, often linked to autoimmune mechanisms. The condition can be challenging to treat, especially in patients with concurrent autoimmune diseases like multiple sclerosis. Understanding the role of B cells in uveitis pathogenesis may open new therapeutic avenues for patients who do not respond to conventional treatments.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
Ofatumumab led to sustained clinical remission in a patient with refractory panuveitis.
The patient had previously failed multiple conventional and experimental treatments, including alemtuzumab.
This case underscores the potential involvement of B cells in the pathogenesis of non-infectious uveitis.
Coexisting autoimmune conditions, such as multiple sclerosis, complicate the management of uveitis.
B-cell–targeted therapies may represent a viable option for refractory cases of uveitis.
Clinical Implications
Clinicians should consider B-cell–targeted therapies like ofatumumab for patients with refractory non-infectious uveitis, especially those with multiple sclerosis. This approach may improve visual outcomes and overall disease management in complex cases.
Conclusion
The successful use of ofatumumab in this case highlights the need for further research into B-cell involvement in uveitis and the potential for targeted therapies in refractory cases.
